US 12,240,873 B2
Respiratory syncytial virus (RSV) vaccine
Thomas Kramps, Tübingen (DE); Margit Schnee, Tübingen (DE); Daniel Voss, Tübingen (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Aug. 12, 2024, as Appl. No. 18/800,440.
Application 18/800,440 is a continuation of application No. 18/616,134, filed on Mar. 25, 2024, granted, now 12,139,513.
Application 18/616,134 is a continuation of application No. 18/463,276, filed on Sep. 7, 2023, granted, now 11,965,000, issued on Apr. 23, 2024.
Application 18/463,276 is a continuation of application No. 18/348,042, filed on Jul. 6, 2023, abandoned.
Application 18/348,042 is a continuation of application No. 17/316,834, filed on May 11, 2021, granted, now 11,739,125, issued on Aug. 29, 2023.
Application 17/316,834 is a continuation of application No. 16/168,747, filed on Oct. 23, 2018, granted, now 11,034,729, issued on Jun. 15, 2021.
Application 16/168,747 is a continuation of application No. 15/488,815, filed on Apr. 17, 2017, granted, now 10,150,797, issued on Dec. 11, 2018.
Application 15/488,815 is a continuation of application No. 15/048,439, filed on Feb. 19, 2016, granted, now 9,688,729, issued on Jun. 27, 2017.
Application 15/048,439 is a continuation of application No. PCT/EP2014/002301, filed on Aug. 21, 2014.
Claims priority of application No. PCT/EP2013/002518 (WO), filed on Aug. 21, 2013.
Prior Publication US 2024/0391962 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); C07K 16/10 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); C07K 16/1027 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/6031 (2013.01); A61K 48/00 (2013.01); C07K 2317/24 (2013.01); C12N 2760/18534 (2013.01)] 46 Claims
 
1. A purified antigen-providing mRNA molecule with a coding region comprising an antigen coding sequence, said mRNA molecule comprising, from 5′ to 3′:
(a) a 5′ Cap structure;
(b) a 5′ untranslated region (UTR) that is heterologous to the antigen coding region;
(c) the antigen coding sequence encoding a Respiratory Syncytial Virus fusion protein (RSV-F) antigen at least 85% identical to the RSV-F encoded by SEQ ID NO: 33, said RSV-F antigen lacking amino acids 554-574 of native RSV-F protein, wherein said RNA coding sequence is at least 80% identical to the protein coding portion of the sequence of SEQ ID NO: 33,
(d) a 3′ UTR that is heterologous to the antigen coding region; and
(e) a poly (A) sequence of 60 to 250 consecutive adenosine nucleotides.